Updates are available Correction dated 2022-07-13

Article History

Received: 22 December 2021

Accepted: 3 June 2022

First Online: 14 June 2022

Change Date: 13 July 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00380-022-02139-3

Declarations

:

: T.O. received research grants from Ono Pharmaceutical Co. Ltd., Bayer Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharma Inc., and Amgen Astellas BioPharma K.K. outside of the submitted work. T.O. received honoraria from Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., and Medtronic Japan Co. Ltd. T.M. received lecture fees from Bayer Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., Sumitomo Pharma Co. Ltd., Kowa Co. Ltd., MSD K. K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K. K., Pfizer Japan Inc., Sanofi-Aventis K. K., and Takeda Pharmaceutical Co. Ltd. T.M. received an unrestricted research grant from the Department of Cardiology, Nagoya University Graduate School of Medicine, from Astellas Pharma Inc., Daiichi-Sankyo Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kowa Co. Ltd., MSD K. K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K. K., Otsuka Pharma Ltd., Pfizer Japan Inc., Sanofi-Aventis K. K., Takeda Pharmaceutical Co. Ltd., and Teijin Pharma Ltd. The authors declare that they have no conflicts of interest.

: The study protocol complied with the 1964 Declaration of Helsinki and its later amendments and was approved by the ethics review board of our institute (Approval Number: 2017–0031), and written informed consent was obtained from all the patients.

: Written informed consent was obtained from all patients for participation.

: Written informed consent was obtained from all patients for publication of data.